SOURCE: AtheroGenics

June 12, 2007 07:00 ET

AtheroGenics to Present at the Sixth Annual Needham Biotechnology & Medical Technology Conference on June 13, 2007

ATLANTA, GA--(Marketwire - June 12, 2007) - AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced its participation in the upcoming Sixth Annual Needham Biotechnology & Medical Technology Conference on Wednesday, June 13, 2007, at 8:00 a.m. EDT at The New York Palace Hotel in New York City.

A live audio webcast of the presentation will be available on the AtheroGenics Investor Relations Events website at http://www.atherogenics.com. A replay of the presentation will be available on the Company's website approximately twenty-four hours after the presentation and will be archived for thirty days.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drug products for the treatment of chronic inflammatory diseases, including diabetes and heart disease (atherosclerosis). AtheroGenics' lead compound, AGI-1067, has completed a Phase III clinical trial as an oral therapy for the treatment of atherosclerosis. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. For more information about AtheroGenics, please visit http://www.atherogenics.com.

Contact Information

  • CONTACTS:

    Corporate Communications
    Donna L. Glasky
    AtheroGenics, Inc.
    678-336-2517
    Email Contact

    Media Inquiries
    Jayme Maniatis
    Schwartz Communications, Inc.
    781-684-0770
    Email Contact

    Investor Inquiries
    Lilian Stern
    Stern Investor Relations, Inc.
    212-362-1200
    Email Contact